Industries > Pharma > Global Rare Disease Drugs Market Forecast 2019-2029

Back to Pharma Reports

Global Rare Disease Drugs Market Forecast 2019-2029

Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies

PUBLISHED: 01 August 2019

PAGES: 250

PRODUCT CODE: PHA0461

SUBMARKET: Therapeutic Drugs

SKU: PHA0461 Categories: Pharma, Therapeutic Drugs Tags: PHA0461, PHA0526, PHA0575, PHA0670

The global rare disease drugs market is estimated to reach $257bn in 2024 and is expected to grow at a CAGR of 11.3% throughout the forecast period. In 2018, rare oncology diseases segment held 36% of share in the global rare disease drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 145 charts– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global rare disease drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

• Global Rare Disease Drugs Market forecasts from 2019-2029

• Revenue forecasts for the global rare disease drugs market by application from 2019-2029:
• Rare Oncology Diseases
• Rare Metabolic Diseases
• Rare Neurologic Diseases
• Rare Hematology Diseases
• Rare Infectious Diseases
• Other Rare Diseases

• Revenue forecasts for the global rare disease drugs market by distribution channel from 2019-2029:
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

• Revenue forecasts for the global rare disease drugs market by drug from 2019-2029:
• Avonex
• Copaxone
• Gleevec
• Imbruvica
• MabThera/Rituxan
• Opdivo
• Rebif
• Revlimid
• Sprycel
• Tasigna
• Velcade
• Other Drugs

• Revenue forecasts for the rare disease drugs market by Regional and National Market from 2019-2029:
• North America (US, Canada)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (Japan, China, India, South Korea)
• RoW (Brazil, Mexico, South Africa, Russia)

• Profiles and discussion on the leading companies in the rare disease drugs market:
• AbbVie
• Bristol-Myers Squibb (BMS)
• Celgene
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi
• Takeda
• Teva

• Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs.

• SWOT Analysis and Porter’s Five Forces analysis of the global rare disease drugs market

• Discussion on factors that drive and restrain the global rare disease drugs market as well as opportunities in this market.

• Key Questions Answered by this Report:
• What are the global revenue prospects for the period 2019 to 2029?
• What are the leading national market potentials from 2019 to 2029?
• How is the rare disease drugs market evolving?
• What is driving and restraining the rare disease drugs market?
• What are the market shares of each segment of the overall rare disease drugs market?
• How will main rare disease drugs submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each rare disease drugs submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

Visiongain’s study is intended for anyone requiring commercial analyses for the Global Rare Disease Drugs Market. You find data, trends and predictions.

Buy our report today Global Rare Disease Drugs Market Analysis: Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

1. Report Overview

1.1 Global Rare Disease Drugs Market Overview

1.2 Global Rare Disease Drugs Market Segmentation

1.3 Overview of Findings

1.4 Structure of the Report

1.5 Why You Should Read This Report

1.6 Key Questions Answered by This Analytical Report

1.7 Who is This Report For?

1.8 Methods of the Study

1.9 Frequently Asked Questions (FAQ)

1.10 Associated Visiongain Reports

1.11 About Visiongain

2. Introduction to Rare Diseases

2.1 What Are Rare Diseases?

2.2 Characteristics of Rare Diseases

2.3 Rare Disease Facts and Statistics

2.4 Enduring Challenges of Rare Diseases

2.5 Types of Rare Diseases

2.5.1 Rare Oncology Diseases

2.5.2 Rare Metabolic Diseases

2.5.3 Rare Neurologic Diseases

2.5.4 Rare Hematology Diseases

2.5.5 Rare Infectious Diseases

2.5.6 Other Rare Diseases

3. Rare Diseases: World Market 2019-2029

3.1 Rare Disease Drugs Market Overview, 2018

3.2 The World Rare Disease Drugs Market

3.3 World Rare Disease Drugs Market: Sales Forecast 2019-2029

3.4 Changing Market Shares by Region 2019-2029

4. Rare Diseases: Qualitative Analysis 2019-2029

4.1 Rare Disease Drugs Market: Drivers 2019-2029

4.1.1 Increase in Prevalence of Rare Diseases

4.1.2 High Investment in Rare Disease Drugs R&D

4.1.3 Increase in Number of Product Approvals

4.1.4 Growing Support of Government for Rare Diseases

4.2 Rare Disease Drugs Market Restraints: 2019-2029

4.2.1 Challenges in Treatment

4.2.2 Challenges in Research and Development

4.2.3 Stringent Government Regulations

4.3 Rare Disease Drugs Market Opportunities: 2019-2029

4.3.1 Progress in Diagnostics and Therapeutics

4.3.2 Orphan Drug Opportunities

4.3.3 IRDiRC Guidelines and Policies

5. Rare Disease Drugs Market by Drugs, 2019-2029

5.1 Market Overview

5.2 Market Forecast 2019-2029

5.2.1 Revlimid: Market Forecast, 2019-2029

5.2.2 MabThera/Rituxan: Market Forecast, 2019-2029

5.2.3 Opdivo: Market Forecast, 2019-2029

5.2.4 Imbruvica: Market Forecast, 2019-2029

5.2.5 Sprycel: Market Forecast, 2019-2029

5.2.6 Avonex: Market Forecast, 2019-2029

5.2.7 Tasigna: Market Forecast, 2019-2029

5.2.8 Copaxone: Market Forecast, 2019-2029

5.2.9 Rebif: Market Forecast, 2019-2029

5.2.10 Gleevec: Market Forecast, 2019-2029

5.2.11 Velcade: Market Forecast, 2019-2029

5.2.12 Other Drugs: Market Forecast, 2019-2029

6. Rare Disease Drugs Market by Applications, 2019-2029

6.1 Market Overview

6.2 Market Forecast 2019-2029

6.3 Rare Oncology Diseases Market

6.4 Rare Metabolic Diseases Market

6.5 Rare Neurologic Diseases Market

6.6 Rare Hematology Diseases Market

6.7 Rare Infectious Diseases Market

6.8 Other Rare Diseases Market

7. Rare Disease Drugs Market by Distribution Channel 2019-2029

7.1 Market Overview

7.2 Market Forecast 2019-2029

7.3 Specialty Pharmacies

7.4 Hospital Pharmacies

7.5 Retail Pharmacies

8. Rare Disease Drugs Market - Pipeline Analysis 2019-2029

8.1 Innovative Rare Disease Drugs Pipeline

8.1.1 Rare Oncology Drugs in Development

8.1.2 Rare Autoimmune Disease Drugs in Development

8.1.3 Blood-related Rare Disease Drugs in Development

8.1.4 Rare Genetic Disease Drugs in Development

8.1.5 Rare Infectious Disease Drugs in Development

9. Leading National Markets 2019-2029

9.1 Geographical Breakdown of the World Rare Disease Drugs Market

9.2 Global Rare Disease Drugs Market: Regional Forecast 2019-2029

9.3 How Will Regional Market Shares Change to 2029?

9.4 North America Rare Disease Drugs Market, 2019-2029

9.4.1 US Rare Disease Drugs Market Forecast 2019-2029

9.4.2 Canada Rare Disease Drugs Market Forecast 2019-2029

9.5 Europe Rare Disease Drugs Market, 2019-2029

9.5.1 Europe Rare Disease Drugs Market Forecast 2019-2029

9.5.2 Germany Rare Disease Drugs Market Forecast 2019-2029

9.5.3 UK Rare Disease Drugs Market Forecast 2019-2029

9.5.4 French Rare Disease Drugs Market Forecast 2019-2029

9.5.5 Italian Rare Disease Drugs Market Forecast 2019-2029

9.5.6 Spanish Rare Disease Drugs Market Forecast 2019-2029

9.6 Asia-Pacific Rare Disease Drugs Market 2019-2029

9.6.1 Japanese Rare Disease Drugs Market Forecast 2019-2029

9.6.2 Chinese Rare Disease Drugs Market 2019-2029

9.6.3 Indian Rare Disease Drugs Market 2019-2029

9.6.4 South Korea Rare Disease Drugs Market Forecast 2019-2029

9.7 RoW Rare Disease Drugs Market 2019-2029

9.7.1 Brazilian Rare Disease Drugs Market Forecast 2019-2029

9.7.2 Mexico Rare Disease Drugs Market 2019-2029

9.7.3 Russia Rare Disease Drugs Market Forecast 2019-2029

9.7.4 South Africa Rare Disease Drugs Market Forecast 2019-2029

10. Leading Companies in the Rare Disease Drugs Market

10.1 Hoffmann-La Roche Ltd.

10.1.1 Financial Overview

10.1.2 Recent Developments

10.2 AbbVie

10.2.1 Financial Overview

10.2.2 Recent Developments

10.3 Pfizer

10.3.1 Financial Overview

10.3.2 Recent Developments

10.4 Takeda Pharmaceuticals

10.4.1 Financial Overview

10.4.2 Recent Developments

10.5 Bristol-Myers Squibb Company

10.5.1 Financial Overview

10.5.2 Recent Developments

10.6 Merck & Co., Inc.

10.6.1 Financial Overview

10.6.2 Recent Developments

10.7 Novartis AG

10.7.1 Financial Overview

10.7.2 Recent Developments

10.8 Celgene Corporation

10.8.1 Financial Overview

10.8.2 Recent Developments

10.9 Teva Pharmaceuticals

10.9.1 Financial Overview

10.9.2 Recent Developments

10.10 Sanofi S.A.

10.10.1 Financial Overview

10.10.2 Recent Developments

11. Rare Disease Drugs Market, Qualitative Analysis, 2019-2029

11.1 Rare Disease Drugs Market: SWOT Analysis, 2019-2029

11.1.1 Strengths

11.1.1.1 Promising Rare Disease Drugs R&D Pipeline

11.1.1.2 Increase in Healthcare Awareness

11.1.2 Increase in Number of Drug Approvals

11.1.3 Weaknesses

11.1.4 High Research and Development Cost

11.1.5 Opportunities

11.1.6 Demand from Emerging Market Continues

11.1.7 Increase in Government Support

11.1.8 Threats

11.1.9 Uncertainty of R&D Results

11.1.10 Barriers to Market Entry

11.2 Rare Disease Drugs Market: Porters Five Forces Analysis, 2019-2029

11.2.1 Bargaining Power of Supplier: Moderate

11.2.2 Bargaining Power of Buyer: Low

11.2.3 Competitive Rivalry: High

11.2.4 The Threat of New Entrants: Low

11.2.5 Threat of Substitutes: Low

12. Conclusion

Associated Visiongain Reports

Visiongain Report Sales Order Form

About Visiongain

Report Evaluation Form

List of Tables

Table 2.1 List of Major Rare Oncology Diseases

Table 2.2 List of Metabolic Diseases

Table 2.3 List of Neurologic Diseases

Table 2.4 List of Hematology Diseases

Table 2.5 List of Some of the Major Other Rare Diseases

Table 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 5.1 Global Rare Disease Drugs Market Forecast by Drugs: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 5.2 Global Revlimid Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.3 Global MabThera/Rituxan Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.4 Global Opdivo Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.5 Global Imbruvica Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.6 Global Sprycel Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.7 Global Avonex Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.8 Global Tasigna Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.9 Global Copaxone Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.10 Global Rebif Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.11 Global Gleevec Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.12 Global Velcade Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 5.13 Global Other Drugs Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 6.1 Global Rare Disease Drugs Market Forecast by Application: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 6.2 Global Rare Oncology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 6.3 Global Rare Metabolic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 6.4 Global Rare Neurologic Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 6.5 Global Hematology Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 6.6 Global Infectious Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 6.7 Other Rare Diseases Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 7.1 Global Rare Disease Drugs Market Forecast by Distribution Channel: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 7.2 Global Specialty Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 7.3 Global Hospital Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 7.4 Global Retail Pharmacies Market Forecast Revenue ($bn), AGR (%), CAGR (%) 2019-2029

Table 8.1 Rare Oncology Drugs in Development, 2018

Table 8.2 Rare Autoimmune Disease Drugs in Development, 2018

Table 8.3 Blood-related Rare Disease Drugs in Development, 2018

Table 8.4 Rare Genetic Disease Drugs in Development, 2018

Table 8.5 Rare Infectious Disease Drugs in Development, 2018

Table 9.1 World Rare Disease Drugs Market by Region: Revenue ($bn) and Market Share (%) 2018 and 2029

Table 9.2 Global Rare Disease Drugs Market Forecast by Region: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.3 North America Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.4 North America Rare Disease Drugs Market by Region Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.5 US Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.6 Canada Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.7 Europe Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.8 Europe Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.9 Germany Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.10 UK Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.11 French Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.12 Italian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.13 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.14 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.15 Asia-Pacific Rare Disease Drugs Market Forecast by Country: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.16 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.17 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.18 Indian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.19 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.20 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.21 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.22 Russia Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 9.23 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn), AGR (%), CAGR (%), 2019-2029

Table 10.1 Overview: Hoffmann-La Roche Ltd.

Table 10.2 Overview: AbbVie

Table 10.3 Overview: Pfizer

Table 10.4 Overview: Takeda Pharmaceuticals

Table 10.5 Overview: Bristol-Myers Squibb Company

Table 10.6 Overview: Merck & Co., Inc

Table 10.7 Overview: Novartis

Table 10.8 Overview: Celgene Corporation

Table 10.9 Overview: Teva Pharmaceuticals

Table 10.10 Overview: Sanofi S.A.

List of Figures

Figure 1.1 Global Rare Disease Drugs Market Segmentation Overview, 2018

Figure 3.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029

Figure 3.2 Global Rare Disease Drugs Market Forecast Share (%) by Region 2019-2029

Figure 4.1 Rare Disease Drugs Market: Drivers 2019-2029

Figure 4.2 Rare Disease Drugs Market: Restraints 2019-2029

Figure 4.3 Rare Disease Drugs Market: Trends 2019-2029

Figure 5.1 Global Rare Disease Drugs by Drugs Market Share Forecast (%) 2019-2029

Figure 5.2 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2018

Figure 5.3 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2019

Figure 5.4 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2024

Figure 5.5 Global Rare Disease Drugs Market Forecast by Drugs: Market Shares (%), 2029

Figure 5.6 Global Revlimid Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.7 Global MabThera/Rituxan Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.8 Global Opdivo Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.9 Global Imbruvica Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.10 Global Sprycel Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.11 Global Avonex Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.12 Global Tasigna Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.13 Global Copaxone Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.14 Global Rebif Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.15 Global Gleevec Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.16 Global Velcade Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 5.17 Global Other Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.1 Global Rare Disease Drugs Market Forecast by Application Market Share (%) 2019-2029

Figure 6.2 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2018

Figure 6.3 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2024

Figure 6.4 Global Rare Disease Drugs Market Forecast by Application: Market Shares (%), 2029

Figure 6.5 Global Rare Oncology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.6 Global Rare Metabolic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.7 Global Rare Neurologic Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.8 Global Hematology Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.9 Global Infectious Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 6.10 Other Rare Diseases Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 7.1 Global Rare Disease Drugs by Distribution Channel Market Share (%) 2019-2029

Figure 7.2 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2018

Figure 7.3 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2024

Figure 7.4 Global Rare Disease Drugs by Distribution Channel: Market Shares (%), 2029

Figure 7.5 Global Specialty Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 7.6 Global Hospital Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 7.7 Global Retail Pharmacies Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.1 Global Rare Disease Drugs Market by Region: Revenues (%), 2018

Figure 9.2 Global Rare Disease Drugs Market by Region: Revenues (%), 2024

Figure 9.3 Global Rare Disease Drugs Market by Region: Revenues (%), 2029

Figure 9.4 North America Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.5 North America Rare Disease Drugs Market by Region Forecast: Market Share 2019-2029

Figure 9.6 US Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.7 Canada Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.8 Europe Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.9 Europe Rare Disease Drugs Market by Country: Revenue (%), 2019-2029

Figure 9.10 Germany Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.11 UK Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.12 French Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.13 Italian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.14 Spanish Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.15 Asia-Pacific Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.16 Asia-Pacific Rare Disease Drugs Market by Country: Revenue (%), 2019-2029

Figure 9.17 Japanese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.18 Chinese Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.19 Indian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.20 South Korea Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.21 Brazilian Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.22 Mexico Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.23 Russia Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 9.24 South Africa Rare Disease Drugs Market Forecast: Revenue ($bn) and AGR (%), 2019-2029

Figure 10.1 Hoffmann-La Roche Ltd.: Financial Overview, 2016-2018

Figure 10.2 AbbVie: Financial Overview, 2016-2018

Figure 10.3 Pfizer: Financial Overview: 2016-2018

Figure 10.4 Takeda Pharmaceuticals: Financial Overview 2016-2018

Figure 10.5 Bristol-Myers Squibb Company: Financial Overview 2016- 2018

Figure 10.6 Merck & Co., Inc: Financial Overview 2016-2018

Figure 10.7 Novartis: Financial Overview 2016-2018

Figure 10.8 Celgene Corporation: Financial Overview 2016-2018

Figure 10.9 Teva Pharmaceuticals: Financial Overview 2016-2018

Figure 10.10 Sanofi S.A.: Financial Overview 2016-2018

Figure 11.1 SWOT Analysis of the Global Rare Disease Drugs Market, 2019-2029

Figure 12.1 Global Rare Disease Drugs Market Forecast Revenue ($bn), AGR (%) 2019-2029

Figure 12.2 Global Rare Disease Drugs Market Forecast Share (%, By Region 2018, 2024 & 2029)

AB Science

AbbVie

Acceleron Pharma & Celgene

Acer Therapeutics

Actavis Generics

Actelion Pharmaceuticals

Actinium Pharmaceuticals

Adaptimmune

Aduro BioTech

Advanced Accelerator Applications

Advantagene

Advaxis

Advenchen Laboratories

Affimed Therapeutics & Merck

Agenus

Agios Pharmaceuticals

Akashi Therapeutics

Akcea Therapeutics

Alcobra

Alexion Pharmaceuticals

Alkeus Pharmaceuticals

Allergan

Alnylam Pharmaceuticals

Ambit Biosciences

AmerisourceBergen Corporation

Amgen

Amicus Therapeutics

Andarix Pharmaceuticals

Angimmune

Angiochem

AntiVirus Therapeutics

Applied Genetic Technologies

Araim Pharmaceuticals

Arch Biopartners

arGentis Pharmaceuticals

ARIAD Pharmaceuticals

ArmaGen Technologies

ARMGO Pharma

AROG Pharmaceuticals

ArQule

ArQule

Array BioPharma

Arrowhead Research

Astellas Pharma US

Astex Pharmaceuticals

AstraZeneca

ATARA Biotherapeutics

Atox Bio

aTyr Pharma

Baxalta

Bayer HealthCare Pharmaceuticals

Belrose Pharmaceuticals

BerGenBio

BioBlast Pharma

BioCryst Pharmaceuticals

Biodel

Biogen

BioInvent International

BioLineRx

BioMarin Pharmaceutical

BioNTech

Bio-Path Holdings

Biotest Pharmaceuticals

Blaze Bioscience

bluebird bio

Blueprint Medicines

Boehringer Ingelheim Pharmaceuticals

Bristol-Myers Squibb

Burzynski Research Institute

Caladrius Biosciences

Cancer Advances

Cancer Prevention Pharmaceutical

Capricor Therapeutics

Cardinal Health, Inc.

CASI Pharmaceuticals

Catabasis Pharmaceuticals

Cavion

Celator Pharmaceuticals

Celgene Corporation

Cell Medica

Cell Therapeutics

Cellectar Biosciences

CEL-SCI

Celsion

Celtaxsys

Cempra Pharmaceuticals

CerRx

Cerulean Pharma

ChemoCentryx

Chugai Pharma

Cidara Therapeutics

Cleave Biosciences

Clementia Pharmaceuticals

Clinuvel

Clovis Oncology

Confluence Pharmaceuticals

Corbus Pharmaceuticals

Cornerstone Pharmaceuticals

Cortice Biosciences

Critical Outcome Technologies

Curis

Cyclacel

CymaBay Therapeutics

CytRx

Daiichi Sankyo

Deciphera Pharmaceuticals

Delcath Systems

DelMar Pharmaceuticals

Diffusion Pharmaceuticals

Dimension Therapeutics

Diurnal

DNAtrix

Eddingpharm

Edimer Pharmaceuticals

Edison Pharmaceuticals

Eiger Biopharmaceuticals

Eisai

Eleison Pharmaceuticals

Eli Lilly

EMD Serono & Pfizer

Emergent BioSolutions

Emmaus Medical

Epitopoietic Research

Epizyme

Epizyme

EryDel

Escala Therapeutics

Essentialis

Five Prime Therapeutics

Fortress Biotech

Gamida Cell

Gem Pharmaceuticals

Gen Sight Biologics

Genentech

GenSpera

Genzyme

Gilead Sciences

GlaxoSmithKline

Gliknik

Global Blood Therapeutics

GlycoMimetics

Golden Biotechnology

Gradalis

Grifols Therapeutics

GW Pharma

Halozyme Therapeutics

Hanmi

Hoffmann-La Roche Ltd

Horizon Pharma

Idera Pharmaceuticals

Ignyta

Immatics Biotechnologies

Immune Design

Immune Pharmaceuticals

Immune Response BioPharma

Immune Therapeutics

ImmunoCellular Therapeutics

ImmunoGen

Immunomedics

Immunovaccine Technologies

Incyte

Infinity Pharmaceuticals

InnoPharma

Insmed

Insys Therapeutics

Ionis Pharmaceuticals

Ionis Pharmaceuticals

Ipsen Biopharmaceuticals

IRX Therapeutics

Janssen Biotech

jCyte

Juno Therapeutics

Karyopharm Therapeutics

Kevelt

Kyowa Kirin USA

LeafBio

Lexicon Pharmaceuticals

Lion Biotechnologies

LipimetiX Development

MabVax Therapeutics

Marathon Pharmaceuticals

Marina Biotech

Mast Therapeutics

McKesson Corporation

MedImmune

MEI Pharma

Merck & Co., Inc

Millendo Therapeutics

Millennium Pharmaceuticals

Milo Biotechnology

Minneamrita Therapeutics

Mirati Therapeutics

Momenta Pharmaceuticals

MorphoSys

Nektar Therapeutics

NeOnc Technologies

Neuren Pharmaceuticals

Neurolixis

Neurotech USA

NGM Biopharmaceuticals

NightstaRx

Nivalis Therapeutics

NKT Therapeutics

Novartis Pharmaceuticals

Novo Nordisk

Novoteris

Ocata Therapeutics

Omeros

On Target Laboratories

Oncolix

Oncolytics Biotech

OncoMed Pharmaceuticals

OncoMed Pharmaceuticals & GlaxoSmithKline

Onconova Therapeutics

OncoPep

Oncopeptides

OPKO Biologics

OSE Pharma

Otsuka Pharmaceutical

OXiGENE

Patagonia Pharmaceuticals

Peregrine Pharmaceuticals

Pfizer Inc.

Pharmacyclics

PharmaCyte Biotech

PharmaEssentia, Corporation

PharmaMar USA

Plexxikon

PNP Therapeutics

Polaris Pharmaceuticals

Polynoma

Prana Biotechnology

Precision Biologics

Progenics Pharmaceuticals

Prolong Pharmaceuticals

Promedior

ProMetic Biotherapeutics

ProNAi Therapeutics

ProQR Therapeutics

Protalex

Provectus Pharmaceuticals

PTC Therapeutics

QLT

Quest PharmaTech

Qurient

Raptor Pharmaceutical

Rebiotx

Regeneron Pharmaceuticals

Regulus Therapeutics & Sanofi US

Retrophin

RetroSense Therapeutics

ReveraGen Biopharma

Rexahn Pharmaceuticals

Rhythm Metabolics

Rigel Pharmaceuticals

River Vision

Roche

Sanofi S. A.

Santhera Pharmaceuticals

Sarepta Therapeutics

Savara Pharmaceuticals

Seattle Genetics

Selexys Pharmaceuticals

SELLAS Life Sciences

Sequella

Seres Health

Shire plc

SIGA Technologies

Sigma-Tau Pharmaceuticals

SillaJen Biotherapeutics

Soligenix

Soricimed Biopharma

Spark Therapeutics

StemcentRx

Stemline Therapeutics

Sun BioPharma

Sun Pharmaceuticals

Sunesis Pharmaceuticals

Takeda Pharmaceuticals

Tapimmune

Tarix Orphan

TESARO

TetraLogic Pharmaceuticals

Teva Pharmaceutical

TG Therapeutics

Tiziana Life Sciences

Tocagen

Tolero Pharmaceuticals

Tracon Pharmaceuticals

TransDerm

Triphase Research & Development

Triphase Research and Development

Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical

uniQure

UroGen

Vascular Biogenics

VentiRx Pharmaceuticals

Verastem

Vertex Pharmaceuticals

Viamet Pharmaceuticals

Vicus Therapeutics

Viralytics

Viventia Biotech

VivoLux

Vtesse

Wilson Therapeutics

Xeris Pharmaceuticals

XOMA

Ziopharm Oncology

Zogenix

Zywie

Download sample pages

Complete the form below to download your free sample pages for Global Rare Disease Drugs Market Forecast 2019-2029

Download sample pages

Complete the form below to download your free sample pages for Global Rare Disease Drugs Market Forecast 2019-2029

Case studies

Need customized work?

Report overview

Methodology

Client testimonials

Pharmaceutical industry associations

American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia

Connect with us

Visiongain Pharma

Latest Pharma news

Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033

The global Automation in Biopharma Industry market was valued at US$1,784.1 million in 2022 and is projected to grow at a CAGR of 5.7% during the forecast period 2023-2033.

20 March 2023

READ

Visiongain Publishes eClinical Solutions Market Report 2023-2033

The global eClinical Solutions market was valued at US$8.03 billion in 2022 and is projected to grow at a CAGR of 13.09% during the forecast period 2023-2033.

17 March 2023

READ

Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033

The global Therapeutic Respiratory Devices market was valued at US$59.49 billion in 2022 and is projected to grow at a CAGR of 8.02% during the forecast period 2023-2033.

15 March 2023

READ

Visiongain Publishes Regenerative Medicine Market Report 2023-2033

The global Regenerative Medicine market was valued at US$ 50.37 billion in 2022 and is projected to grow at a CAGR of 18.40% during the forecast period 2023-2033.

10 March 2023

READ

Industries > Pharma > Global Rare Disease Drugs Market Forecast 2019-2029

Back to Pharma Reports

Global Rare Disease Drugs Market Forecast 2019-2029

Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies

Download sample pages

Related reports

Anti-infective Agents Market Forecast 2019-2029

Orphan Drugs Market Report 2018-2028

Global Inflammatory Bowel Diseases (IBD) Drug Market Forecast 2019-2029

Advanced Wound Care Market Forecast 2019-2029

Attention Deficit Hyperactivity Disorder Drugs Market Forecast to 2029

Global Macular Degeneration (AMD) and Other Retinal Diseases Drugs Industry and Market 2019-2029

Translational Regenerative Medicine Market Forecast 2020-2030

Global Diagnostic Imaging Market Forecast 2019-2029

Global Precision Medicine Market Forecast 2019-2029

Global Stem Cell Technologies and Applications Market 2019-2029

Download sample pages

Share

Connect with us

Latest Pharma news

Visiongain Publishes Automation in Biopharma Industry Market Report 2023-2033

Visiongain Publishes eClinical Solutions Market Report 2023-2033

Visiongain Publishes Therapeutic Respiratory Devices Market Report 2023-2033

Visiongain Publishes Regenerative Medicine Market Report 2023-2033

Our Clients